GALACTOSYLATED PROTEINS ARE RECOGNIZED BY THE LIVER ACCORDING TO THE SURFACE-DENSITY OF GALACTOSE MOIETIES

被引:74
作者
NISHIKAWA, M [1 ]
MIYAZAKI, C [1 ]
YAMASHITA, F [1 ]
TAKAKURA, Y [1 ]
HASHIDA, M [1 ]
机构
[1] KYOTO UNIV, FAC PHARMACEUT SCI, DEPT DRUG DELIVERY RES, SAKYO KU, KYOTO 60601, JAPAN
来源
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY | 1995年 / 268卷 / 05期
关键词
HEPATIC TARGETING; ASIALOGLYCOPROTEIN RECEPTOR; PHARMACOKINETICS; SUPEROXIDE DISMUTASE; BOVINE SERUM ALBUMIN;
D O I
10.1152/ajpgi.1995.268.5.G849
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The recognition of In-111-labeled galactosylated superoxide dismutase (Gal-SOD) and galactosylated bovine serum albumin (Gal-BSA) by the liver was investigated in mice after intravenous injection. In-111-labeled galactosylated proteins were recovered in the liver by amounts that were highly dependent on the degree of galactose modification and the administered dose. The distribution patterns were analyzed based on a physiological pharmacokinetic model including an uptake process with Michaelis-Menten kinetics in the liver and hepatic plasma flow. The Michaelis constant of hepatic uptake of In-111-Gal-SOD was observed to inversely correlate with the number of galactose residues, without a significant change in maximum rate of uptake or extrahepatic clearance. This relation could be applied to In-111-Gal-BSA and other galactosylated proteins by using the surface density of galactose residues as a degree of modification, suggesting galactose density controls ligand recognition by the asialoglycoprotein receptor. The analysis also indicated that increasing galactose density higher than 1.0 x 10(-3) molecules/Angstrom 2 did not affect the distribution of galactosylated proteins due to limitation by the hepatic plasma flow rate. In conclusion, efficient delivery of proteins modified with galactose to the liver will be achieved by controlling both the galactose density on the protein surface and the administered dose.
引用
收藏
页码:G849 / G856
页数:8
相关论文
共 30 条
[1]   CARBOHYDRATE-SPECIFIC RECEPTORS OF THE LIVER [J].
ASHWELL, G ;
HARFORD, J .
ANNUAL REVIEW OF BIOCHEMISTRY, 1982, 51 :531-554
[2]   GLOMERULAR PERMSELECTIVITY - BARRIER FUNCTION BASED ON DISCRIMINATION OF MOLECULAR-SIZE AND CHARGE [J].
BRENNER, BM ;
HOSTETTER, TH ;
HUMES, HD .
AMERICAN JOURNAL OF PHYSIOLOGY, 1978, 234 (06) :F455-F460
[3]   RENAL TUBULAR UPTAKE OF PROTEIN - EFFECT OF MOLECULAR CHARGE [J].
CHRISTENSEN, EI ;
RENNKE, HG ;
CARONE, FA .
AMERICAN JOURNAL OF PHYSIOLOGY, 1983, 244 (04) :F436-F441
[4]  
CONNOLLY DT, 1982, J BIOL CHEM, V257, P939
[5]  
DUNCAN JR, 1993, J NUCL MED, V34, P1728
[6]  
FALLON R J, 1989, Advanced Drug Delivery Reviews, V4, P49, DOI 10.1016/0169-409X(89)90037-9
[7]   CONTROL OF IN-VIVO FATE OF ALBUMIN DERIVATIVES UTILIZING COMBINED CHEMICAL MODIFICATION [J].
FUJITA, T ;
NISHIKAWA, M ;
OHTSUBO, Y ;
OHNO, J ;
TAKAKURA, Y ;
SEZAKI, H ;
HASHIDA, M .
JOURNAL OF DRUG TARGETING, 1994, 2 (02) :157-165
[8]   THERAPEUTIC EFFECTS OF SUPEROXIDE-DISMUTASE DERIVATIVES MODIFIED WITH MONOSACCHARIDES OR POLYSACCHARIDES ON HEPATIC-INJURY INDUCED BY ISCHEMIA REPERFUSION [J].
FUJITA, T ;
FURITSU, H ;
NISHIKAWA, M ;
TAKAKURA, Y ;
SEZAKI, H ;
HASHIDA, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1992, 189 (01) :191-196
[9]  
FUJITA T, 1992, J PHARMACOL EXP THER, V263, P971
[10]   PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING - PRINCIPLES AND APPLICATIONS [J].
GERLOWSKI, LE ;
JAIN, RK .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1983, 72 (10) :1103-1127